Market Size (2018)
$12.17B
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$12.17B
Projected (2025)
$15.06B
CAGR (2016–2025)
3.1%
Key Players
10+
Allergic rhinitis, also known as hay fever, is an allergic disease associated with the nose. The allergic rhinitis affects when the immune system of the human body becomes sensitized and overreacts to specific allergens in the environment which are generally not harmful to most of the people. Allergic rhinitis can be categorized as three different types viz., seasonal, perennial, and occupational.
Key Contributing Factors
There are numerous factors that contribute to the growth of the allergic rhinitis market. The key factors are mentioned below in brief.
Rising Prevalence of Allergic Rhinitis
According to the American Academy of Asthma & Immunology, allergic rhinitis affects 10% to 30 % of the global population. Additionally, National Center for Biotechnology Information (NCBI) reported that the prevalence of allergic rhinitis in the US is approximately 15% based on the physician’s diagnosis and as high as 30% on the basis of self-reported nasal symptoms.
Government Initiatives to Create Awareness
International organizations are creating awareness in order to address diagnosis, management, prevention, and awareness of chronic obstructive lung disease. For instance, Allergic Rhinitis and its Impact on Asthma (ARIA), has collaborated with the World Health Organization (WHO), to educate and implement evidence-based management for allergic rhinitis and asthma worldwide.
Increasing Healthcare Expenditure
Respiratory disease is a huge burden on society in terms of disability and premature mortality, and also indirect health service costs, drugs prescribed, and the indirect costs related to lost production. For instance, according to a survey by the NCBI, the average per-patient expenditure for prescription medication was USD 657 yearly.
The Allergic Rhinitis Market market is projected to grow at a CAGR of 3.1% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAllergic Rhinitis Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
Allergic rhinitis is caused due to sensitization of the immune system in response to allergens, which are generally harmless for most individuals. The sensitization results in the overreaction of the immune system causing inflammation of nose, congestion, sinus pressure, and sneezing, among other symptoms.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global allergic rhinitis services market is characterized by the presence of global, regional, and local vendors. The market is highly competitive with all players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share. Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
The top players in the global allergic rhinitis market are GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Bayer AG and Sanofi.
GlaxoSmithKline plc operates in four segments namely; pharmaceuticals, pharmaceuticals R&D, vaccines, and consumer healthcare. The company offers healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescent, lozenges, gum and trans-dermal patches. GlaxoSmithKline plc holds First position in global allergic rhinitis market with 9.81% market share.
Johnson & Johnson Services, Inc. accounted for the second-largest market share of 9.12% in 2018. It is 130-year-old company and it has strong presence over the globe. The company has more than 125,000 employees in more than 60 countries. The company offers products in segments such as consumer, pharmaceuticals and medical devices. It is one of the major players in the global allergic rhinitis market and it has strong presence in established markets.
Bayer AG accounted for 6.93% market share of global allergic rhinitis market in 2018. The company is present in all established markets and has strong brand name in the market. It operates in business segments including human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals, and biotechnology products, and high-value polymers.
Sanofi held third position in the allergic rhinitis market with 4.76% market share. It is a French multinational pharmaceutical company which functions through three segments, namely, pharmaceuticals, consumer healthcare, and vaccines. The company serves its customers around the globe with having presence in more than 100 countries and industrial sites in 38 countries. Sanofi mostly emphasizes on new product launches and invests in sales and marketing activities.
Few other major market value contributors operating in this market are Boehringer Ingelheim, Merck & Co., ALK-Abelló A/S, and Meda Pharmaceuticals.
Bargaining Power of Suppliers
The bargaining power of suppliers in the allergic rhinitis market is moderate. The number of suppliers in the market is sufficiently high to provide plenty of options to drug manufacturers for material sourcing which is required for the production of the various drugs, thus leaving suppliers with moderate bargaining power. Another factor affecting the bargaining power of suppliers is the supplier switching cost for buyers owing to the presence of a moderate number of raw material suppliers in the market. On the other hand, only a moderate number of viable raw material substitutes are available, which further boosts the bargaining power of suppliers in the market.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global allergic rhinitis market. The market has a moderate number of buyers for various allergic rhinitis treatment drugs. The buyers of allergic rhinitis treatment in the global market are highly inclined towards brand identity. Moreover, the buyers can exert moderate to high pressure on the drugs manufacturing companies as some of the companies provide their product at a high cost. Hence, due to the presence of a large number of companies and a huge number of products, the bargaining power of buyers tends to be moderate.
Threat of New Entrants
The threat of new entrants is moderate to high in the global allergic rhinitis market. Prevalence of allergic rhinitis is increasing significantly, which has increased the demand for new drugs. Moreover, increasing geriatric population and funding is influencing many of the start-ups to take a keen interest in the field of research & development. Introduction of new drugs requires a long-time clinical trial and a huge capital. This is the reason that there are moderate to high possibilities for new entrants in the market.
Threat of Substitutes
The threat of substitutes in the global allergic rhinitis market is low. There are a very few substitute treatment methods which pose a low threat in the global allergic rhinitis market.
Intensity of Rivalry
The degree of competition in the global allergic rhinitis market is moderate to high. People are more inclined to brand identity. However, increasing government support and the availability of funding has encouraged many new start-ups. To compete with multinational players, new and small companies are reducing the cost of their products, which makes the intensity of rivalry moderate to high.
Market estimates by geography (2025)
InsightEurope leads with $5.19B by 2025, while Asia Pacific is projected to grow fastest at a 3.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $818.78M | $954.04M | $1.08B | 3.1% | 7% |
| Americas | $4.11B | $4.63B | $5.10B | 2.4% | 34% |
| Asia Pacific | $2.68B | $3.21B | $3.70B | 3.6% | 25% |
| Europe | $3.84B | $4.54B | $5.19B | 3.4% | 34% |
| Total | $11.45B | $13.33B | $15.06B | 3.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$15.06B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Seasonal Allergic Rhinitis | $7.67B | 3.2% | 55% |
| Perennial Allergic Rhinitis | $5.37B | 3.4% | 38% |
| Occupational Allergic Rhinitis | $1.00B | 1.4% | 7% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Allergic Rhinitis Market covering market dynamics, competitive landscape, and strategic outlook.
The Allergic Rhinitis Market market is projected to reach $15.06B by 2025, growing at 3.1% CAGR. The Seasonal Allergic Rhinitis segment holds the largest share.
Allergic rhinitis also known as hay fever is a type of inflammation which occurs due to the allergic response to specific allergens in the air. Allergic rhinitis treatment includes medications such as corticosteroids, antihistamines, nasal sprays, and leukotriene modifier.
The global allergic rhinitis market is emerging due to the increasing prevalence of allergic rhinitis, increasing government initiatives to promote awareness regarding allergic rhinitis, and growing healthcare expenditure and expansion of the private healthcare system.
However, the complications and side effects arising from allergic rhinitis medications and patent expiry are hampering the growth of the market.
Likewise, increasing demand in developing countries and exploring advanced products are likely to pose as an opportunity for the allergic rhinitis market.
Allergic rhinitis is an inflammation of the nose caused by inhaling allergens such as pollen or dust. The allergic rhinitis market is witnessing considerable growth due to the rising prevalence of hay fever among the population. For instance, according to the American Academy of Asthma & Immunology, allergic rhinitis affects 10% to 30 % of the global population. Additionally, National Center for Biotechnology Information (NCBI) reported that the prevalence of allergic rhinitis in the US is approximately 15% based on the physician’s diagnosis and as high as 30% on the basis of self-reported nasal symptoms.
Furthermore, the European Academy of Allergy and Clinical Immunology (EAACI), stated that over 150 million Europeans suffer from chronic allergic disease, out of which 100 million Europeans suffer from allergic rhinitis. Additionally, the NCBI stated that the prevalence of allergic rhinitis has increased in high-income countries, due to a significant rise in air pollutants.
The increasing number of patients affected with allergic rhinitis across the globe is driving the growth of the allergic rhinitis market.
Developing countries with a large population and recent developments provide a great opportunity for the companies and for device manufacturers to flourish in the market. The developing infrastructure and healthcare expenditure in Africa, India, and other countries provide large opportunities to allergic rhinitis market companies. These countries and the rapid advancements of technology are expected to record higher cases of asthma and COPDs which are currently undiagnosed. These developing countries are likely to witness a growth in the per capita disposable incomes which will eventually increase the affordability for these people for the treatment.
Allergic rhinitis market is facing a major threat in the form of patent expiry which is likely to hamper the market in the near future. Major market players and their drugs are either losing patent or are undergoing lawsuits regarding retaining their patency. For instance, Avamys/Veramyst nasal spray by GlaxoSmithKline is a corticosteroid treatment indicated for the treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children above two years. This drug is likely to lose its patent in 2021 in the US, and in 2023 in the European Union (EU).
Apotex sought permission from the Food and Drug Administration (FDA) to manufacture the generic version of Dymista nasal spray before the patent expiry. However, generic drug maker Cipla Ltd and its American partner Meda Pharmaceuticals Inc. have jointly sued the Apotex group in the US to defend patent rights for its Dymista nasal spray, which is used to treat seasonal allergic rhinitis.
This lawsuit and patent expiry are hampering the growth of the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 103 companies operating in the Allergic Rhinitis Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Meda Pharmaceuticals
Company Headquarters: Dubai, UAE Founded: 1954 Workforce: ~4,600 Company Working: Meda Pharmaceuticals operates as a subsidiary of Mylan NV and is actively involved in the production, distribution, and marketing of prescription and OTC pharmaceutical products. The company operates through the following business segments— allergy, pain management, gastrointestinal, urology, cardio and CNS, dermatology, and OTC. It has a direct presence in 60 countries and it also offers its products through distributors in more than 150 countries including Australia, China, Italy, South Africa, the UK, and the UAE. More than 50% of its revenue comes from respiratory, dermatology, and pain and inflammation therapeutic areas
Novartis AG
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Bayer AG
Novavax, Inc.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Cleveland Biolabs, Inc
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
SIGA Technologies
Company Headquarters: New York, US Founded: 1995 Workforce: ~50 Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence